Study of anlotinib plus chemo for SMARCA4-deficient lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining anlotinib (a targeted drug that blocks tumor blood vessels) with standard chemotherapy for a rare type of advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combination helps people who haven't had treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB or IV) lung cancer that can't be removed with surgery or treated with radiation to cure it.
- Your tumor has been tested and confirmed to lack the SMARCA4 gene (called SMARCA4-deficient).
- You have not had any previous cancer treatment, like chemotherapy or targeted therapy, for your lung cancer.
- You are 18 or older, able to care for yourself (ECOG score 0 or 1), and doctors expect you to live at least 3 more months.
- You are willing to provide a sample of your tumor (either from a past biopsy or a new one) for extra testing.
- Your blood counts, kidney, and liver function are within acceptable limits, and you don't have serious heart or other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) combined with standard chemotherapy for people with advanced lung cancer that has a specific genetic change (loss of the SMARCA4 gene). The goal is to see if this combination works better than chemo alone.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This trial tests a combination of four drugs (ABCP) as the first treatment for people with advanced non-squamous lung cancer that has a specific gene change called SMARCA4. The goal is to see if this therapy is safe and works well.
Hear when a new SMARCA4-Deficient Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.